Number №3, 2022 - page 110-116

Opportunities to increase early diagnostics and treatment compliance of BPH progression DOI: 10.29188/2222-8543-2022-15-3-110-116

For citation: Evdokimov M.S., Spivak L.G. Opportunities to increase early diagnostics and treatment compliance of BPH progression. Experimental and Clinical Urology, 2022;15(3)110-116; https://doi.org/10.29188/2222-8543-2022-15-3-110-116
Evdokimov M.S., Spivak L.G.
Information about authors:
  • Evdokimov M.S. – PhD, Chief physician, urologist of «Family Policlinic No. 4»; Korolev, Russia; https://orcid.org/0000-0002-1459-5098
  • Spivak L.G. – Dr. Sci., Professor of the Institute of Urology and Human Reproductive Health of I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia; Moscow, Russia; https://orcid.org/0000-0003-1575-6268

Introduction. Benign prostatic hyperplasia (BPH) is one of the most common diseases of the genitourinary system in men. Severe symptoms of lower urinary tract dysfunction (LUTS), which develop with BPH, worsen the quality of life. Prophylactic examinations, dynamic monitoring and necessary treatment: conservative (nonpharmacological and pharmacological treatment) or surgical treatment are necessary to control the course of the disease. Bioregulatory peptides can be used for early control of LUTS.

The aim of the work was to assess the efficacy of early diagnosis and adherence to drug prophylaxis of BPH development and progression using different methods including bioregulatory peptides.

Materials and methods. Data of the clinical examination and periodic medical examinations of 1675 men who were enrolled in the program «Complex of measures to increase the efficiency of early diagnostics of BPH and increase adherence to medical prophylaxis of BPH development and progression» were analyzed. After full clinical examination, depending on indications, patients were recommended surgical or conservative treatment – non-medication (behavioral) or medication (α1-adrenoblockers + muscarinic receptor antagonists, 5α-reductase inhibitors or Vitaprost preparations). The patients were observed for 4 years. Efficacy and safety of the use of bioregulatory peptides (Vitaprost®) in patients with BPH and LUTS were compared with the results of treatment in patients who chose behavioral therapy (active observation).

Results. Behavioral therapy was used in 221 patients with mild to moderate symptoms, 312 patients were prescribed Vitaprost® Forte and Vitaprost® tablets. Active observation was more often chosen by patients of the youngest group (40-44 years). During Vitaprost® application there were improved IPSS questionnaire indexes, maximal urination rate increased, residual urine volume and prostate volume decreased. Worsening and increase of severity of complaints, according to IPSS questionnaire, decrease of maximum urinary flow rate and increase of residual urine volume and prostate volume were registered in actively observed group of patients.

Conclusions. Timely initiation of therapy with Vitaprost® Forte and Vitaprost® tablets in patients with BPH has a favorable efficacy and safety profile. Further analysis of the data received as a result of the regional program is supposed to be carried out to evaluate its results.

Download855.92 KB
benign prostatic hyperplasia; lower urinary tract symptoms; treatment; bioregulatory peptides; active surveillance

Readera - Социальная платформа публикаций

Crossref makes research outputs easy to find, cite, link, and assess